
Bio-Rad Laboratories
Bio-Rad | Products for Life Science Research & Clinical Diagnostics.
USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 15 % | (4 %) | (5 %) | (4 %) | (2 %) | 3 % | 3 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 22 % | 24 % | 22 % | 20 % | 16 % | 17 % | 17 % |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 145 % | (129 %) | (24 %) | (72 %) | 7 % | 7 % | 7 % |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 9 % | 9 % | 9 % | 12 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostics markets. The company serves academic institutions, pharmaceutical companies, biotechnology firms, and clinical laboratories. Bio-Rad operates in the highly competitive life sciences and diagnostics markets, offering products that include reagents, instruments, and software for cell biology, gene expression, protein purification, and imaging. The business model focuses on selling these products directly to customers through a dedicated sales force and online platforms, generating revenue through product sales and service contracts. Bio-Rad's commitment to quality and innovation helps researchers and clinicians advance their discoveries and improve patient outcomes.
Keywords: life science research, clinical diagnostics, reagents, instruments, software, gene expression, protein purification, imaging, biotechnology, pharmaceutical.
Tech stack
Investments by Bio-Rad Laboratories
Edit






